Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe).
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Rituximab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RIVITaLISe
- 25 Mar 2016 Status changed from active, no longer recruiting to discontinued as efficacy on CSF biomarkers failed to reach criteria for continuation of the trial as per ClinicalTrials.gov record.
- 02 Oct 2015 Planned End Date changed from 1 Sep 2017 to 1 Sep 2016, as reported by ClinicalTrials.gov.
- 03 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.